Characterization of aluminum hydroxide gel and oil-in-water emulsion formulations containing CpG ODNs

BioPharm International

Volumn 23, Issue 10 SUPPL., 2010, Pages 14-19

  Fox, Christopher B ^a   Dutill, Timothy S ^a   Chesko, James ^a   Anderson, Ryan C ^b   Reed, Steven G ^a   Vedvick, Thomas S ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b Chemical Abstracts Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CPG OLIGODEOXYNUCLEOTIDE; OIL; WATER;

ADSORPTION KINETICS; ARTICLE; BIOLOGICAL ACTIVITY; BIOPHYSICS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MICROELECTROPHORESIS; PARTICLE SIZE; ULTRAVIOLET SPECTROPHOTOMETRY; ZETA POTENTIAL;

EID: 78650501897     PISSN: 1542166X     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (15)

1. Salem AK. CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Del Rev. 2009;61:193-4.
2. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini, S, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26:552-61.
3. Ott G, Singh M, Kazzaz J, Briones M, Soenawan E, Ugozzoli M, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Control Rel. 2002;79:1-5.
4. Ioannou XP, Gomis SM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine. 2003;21:4368-72.
5. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharm. 2006;6:1267-76.
6. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 1998;95:15553-8.
7. Singh M, Chesko J, Kazzaz J, Ugozolli M, Malyala P, O'Hagan D. Surface-charged poly(lactide-co-glycolide) microparticles as novel antigen delivery systems. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley & Sons; 2007. p. 223-48.
8. Krieg AM. WO/2004/005476, WIPO, Nucleic acid compositions for stimulating immune responses, Coley Pharmaceutical Group, Inc., 2004.
9. CpG ODN Information Sheet, Coley Pharmaceutical Group, 2006.
10. Hem SL, HogenEsch H. Aluminum-containing adjuvants: properties, formulation, and use. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley & Sons; 2007. p. 81-114.
11. Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine. 2004;22:3658-68.
12. Alhydrogel 85 2% Certificate of Analysis. Brenntag Biosector. 2007.
13. Aebig JA, Mullen GED, Dobrescu G, Rausch K, Lamber L, Ajose-Popoola O, et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007;323:139-46.
14. Kritsch CE, Berger A, Heinrich-Cseh C, Bugajska-Schretter A, Zauner W. Separation and quantification of a novel two-component vaccine adjuvant. J Chromatogr B. 2005;822:263-70.
15. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 1998;186:18-27.